Skip to content

A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children

Hematology Oncology Center

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02999308
Acronym
CHIPS
Enrollment
40
Registered
2016-12-21
Start date
2016-08-31
Completion date
2017-12-31
Last updated
2016-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemophilia

Keywords

haemophilia, prophylaxis, children

Brief summary

In the past, due to economic and medical resource constraints, the hemophilia comprehensive care in China was suboptimal. The BCH data of both retrospective and prospective studies reveals that for 4-6y and 6-9y patients with severe hemophilia respectively: 45% and 82% of the patients have suffered from joint bleeding, with mean AJBR of 4.18 and 4.95; and 24.2% and 33.3% of them with AJBR\>10 times, led to arthropathies and made their quality of life be heavy affected. Now, with the development of economy and medical science in China, prophylaxis regimens have been initiated in more and more children with hemophilia. Considering the difference between prophylaxis regimens, the frequency of joint bleeding was reduced significantly, the quality of life of hemophilia kids improved. An assessment scoring system for the appropriate validation of individualized prophylaxis treatment regimens are urgently needed. Before, the most important assessed indication for hemophilia prophylaxis was the frequency of joint bleeding. But increasing evidences are showing that there is a discrepancy between real joint damage and joint bleeding frequency. The single indicator of joint bleeding frequency is not sufficient to evaluate the joint status of hemophilia children. Under the World Health Organization's ICF guidelines, the assessment scoring system for selecting prophylaxis for children with hemophilia should include the tools currently available for assessment of structure/function of the joint, patient activities and patient participation in hemophilia healthcare. According to ICF of WHO, the most common bleeding parts are elbows, knees and ankles, therefore the assessment of children with hemophilia should include the evaluation of the structure, the function of these 6 Index joints, the capacity of activities and the capacity of participation of children. These will constitute a comprehensive hemophilia evaluation system. In China, exploration of the optimal and individualized prophylaxis regimen is urgent, and the comprehensive evaluation system should include joint structure and function, body's activities and individual participation, thus may be more appropriate for the individualized prophylaxis for Chinese children with hemophilia.

Interventions

OTHERObserve the patient's condition and then change the regimen

The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.

Sponsors

Beijing Children's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

1. Severe hemophilia A (FVIII: C\<2%), 2. Age 1-7y 3. Historical bleeding in any knee, elbow and ankle joint (s), 4. \>50 EDs irrespective of FVIII product, including human coagulate factor and recombinant factor VIII 5. No inhibitor present or history/family history, 6. On-demand or low-dose prophylaxis (the dose per kg.week less or as Step 1 prophylaxis regimens factor consumption) 7. Regular clinical visit with accessible data, 8. Informed consent will be obtained from patient legal guardians before the enrollment.

Exclusion criteria

* 1\. Other bleeding disorders or systemic disorders, or don't fit for enrollment according to the investigator, 2. FVIII inhibitor development:\>0.6 BU (confirmed by two separate tests), 3. Unable to follow the protocol or refuse to continue the participation.

Design outcomes

Primary

MeasureTime frame
Change of Ultrasound HEAD-US score of index jointsbaseline,3 months, 6 months,9 months and 12 months

Countries

China

Contacts

Primary ContactWu Runhui, MD, PhD
runhuiwu@hotmail.com0086-010-59617621

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026